ريجدانفيماب
Sign in to saveRegdanvimab, sold under the brand name Regkirona, is a human monoclonal antibody used for the treatment of COVID-19. The antibody is directed against the spike protein of SARS-CoV-2. It is developed by Celltrion. The medicine is given by infusion (drip) into a vein.
In the Vinony graph
Within Vinony's link graph, ريجدانفيماب is referenced by 1,325 other articles, and connects out to monoclonal antibody, casirivimab/imdevimab and AZD7442.
It sits within the topics Antiviral drugs, Chemical pages without ChemSpiderID and COVID-19 drug development.
Its subject is documented across 11 Wikipedia language editions.
Key facts
- Drug.type
- mab
- Drug.mab_type
- mab
- Drug.source
- u
- Drug.target
- Spike protein of SARS-CoV-2
- Drug.tradename
- Regkirona
- Drug.licence_EU
- yes
- Drug.pregnancy_AU
- B2
- Drug.routes_of_administration
- Intravenous
- Drug.ATC_prefix
- J06
- Drug.ATC_suffix
- BD06
- Drug.legal_AU
- S4
- Drug.legal_EU
- Rx-only
- Drug.legal_status
- Rx-only
- Drug.CAS_number
- 2444308-95-4
- Drug.DrugBank
- DB16405
- Drug.UNII
- I0BGE6P6I6
- Drug.KEGG
- D12241
- Drug.synonyms
- CT-P59
via Wikipedia infobox
Connections
monoclonal antibody
Entity
casirivimab/imdevimab
Entity
AZD7442
Medication
SARS-CoV-2
Entity
bamlanivimab/etesevimab
Entity
human
Entity
COVID-19
Entity
fungi
Entity
virus
Entity
bacteria
Entity
digital object identifier
Entity
infection
Entity
PubMed
Entity
antigen
Entity
toxin
Entity
CAS Registry Number
Entity
PubMed Central
Entity
Anatomical Therapeutic Chemical Classification System
Entity
intravenous infusion and defusion
Entity
clinical trial
Entity